PLACENTAL GROWTH FACTOR AND CORONARY NEOANGIOGENESIS IN CORONARY HEART DISEASE
https://doi.org/10.17650/1818-8338-2013-1-4-8
Abstract
Neoangiogenesis in coronary heart disease is a protective reaction aimed to improve ischemic myocardial perfusion, by increasing the number and size of arterial collaterals. Placental growth factor (PlGF) is one of the key peptides regulating angiogenic processes in atherosclerosis. In particular, a number of investigators have shown that injection of recombinant PlGF into the system or regional blood flow can stimulate neoangiogenesis. On the other hand, there is evidence confirming the involvement of PlGF in the progression of atherosclerosis and in the development of acute coronary syndrome. In this connection, the problem of investigating the efficiency and safety of possible use of PlGF preparations, as well as its place in the diagnosis of coronary heart disease and acute coronary syndrome remains urgent
About the Authors
M. V. Tulikov
Clinical Hospital, Department for Presidential Affairs of the Russian Federation
Russian Federation
Russian Federation
O. P. Shevchenko
Faculty for Postgraduate Training of Physicians, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
A. O. Shevchenko
Faculty for Postgraduate Training of Physicians, N.I. Pirogov Russian National Research Medical University, Ministry of Health of Russia
Russian Federation
Department of Cardiology
Russian Federation
Department of Cardiology
A. V. Gagayev
Clinical Hospital, Department for Presidential Affairs of the Russian Federation
Russian Federation
Russian Federation
V. V. Pavlov
Clinical Hospital, Department for Presidential Affairs of the Russian Federation
Russian Federation
Russian Federation
References
1. Felmeden D.C., Blann A.D., Lip G.Y. Angiogenesis: basic pathophysiology and implications for disease. Eur Heart J 2003;24(7):586–603.
2. Apple F.S., Wu A.H., Mair J. et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem 2005;51(5):810–24.
3. Gerber H.P., Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in
4. combination with cytotoxic therapy in preclinical studies. Cancer Res 2005;65(3):671–80.
5. Ribatti D. The discovery of the placental growth factor and its role in angiogenesis: a historical review. Angiogenesis 2008;11(3):215–21.
6. Selvaraj S., Giri R., Perelman N. et al. Mechanism of monocyte activation and expression of proinflammatory cytochemokines by placenta growth factor. Blood 2003;102(4):1515–24.
7. Fam N.P., Verma S., Kutryk M., Stewart D.J. Clinician guide to angiogenesis. Circulation 2003;108(21):2613–8.
8. Takeda Y., Uemura S., Iwama H. et al. Treatment with recombinant placental growth factor (PlGF) enhances both angiogenesis and arteriogenesis and improves survival after myocardial infarction. Circ J 2009;73(9):1674–82.
9. Liu X., Caluwe E. Placental growth factor increases regional myocardial blood flow and function in a new porcine model of chronic myocardial ischemia. Circulation 2009;120:S837.
10. Nutu O., Molinie V., Shen M. et al. Therapeutic role of placenta growth factor in post-infarct myocardial revascularization. Available from: http://circ.ahajournals.org/cgi/content/meeting_abstract/114/18_MeetingAbstracts/II_172.
11. Koester W. Endareritis and arteritis. Berl Klin Wschr 1876;13:454–5.
12. O'Brien E.R., Garvin M.R., Dev R. el al. Angiogenesis in human coronary atherosclerotic plaques. Am J Pathol 1994;145(4):883–94.
13. Moreno P.R., Purushothaman K.R., Fuster V. el al. Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation 2004;110(14):2032–8.
14. Pipp F., Heil M., Issbrücker K. et al. VEGFR-1-selective VEGF homologue PlGF is arteriogenic: evidence for a monocyte-mediated mechanism. Circ Res 2003;92(4):378–85.
15. Moulton K.S., Vakili K., Zurakowski D. et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci USA 2003;100(8):4736–41.
16. Luttun A., Tjwa M., Moons L. et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nat Med 2002;8(8):831–40.
17. Khurana R., Moons L., Shafi S. et al. Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005;111(21):2828–36.
18. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349(9063):1429–35.
19. Heeschen C., Dimmeler S., Fichtlscherer S. et al. Prognostic value of placental growth factor in patients with acute chest pain. JAMA 2004;291(4):435–441.
20. Шевченко О.П., Шевченко А.О., Орлов а О.В., Туликов М.В. Неоангиогенез и коронарный атеросклероз: диагностическое значение нового биохимического маркера – плацентарного фактора роста P1GF – у больных ишемической болезнью сердца. Кардиология 2006;(11):9–15.
21. Cassidy A., Chiuve S.E., Manson J.E. et al. Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol 2009;29(1):134–9.
Review
For citations:
Tulikov M.V., Shevchenko O.P., Shevchenko A.O., Gagayev A.V., Pavlov V.V. PLACENTAL GROWTH FACTOR AND CORONARY NEOANGIOGENESIS IN CORONARY HEART DISEASE. The Clinician. 2013;7(1):4-8. (In Russ.) https://doi.org/10.17650/1818-8338-2013-1-4-8
Views:
948
Email this article 